Company intelligence / Profile preview

Beijing Biohealthcare Biotechnology Co., Ltd.

Beijing, Beijing Municipality, Chinabmsscience.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has advanced several autologous immune cell therapies to Phase 2 clinical trials for oncology indications such as stomach cancer. Other programs are at IND approval or preclinical stages. The company is actively developing a range of cellular immunotherapies targeting solid tumors and viral infections.

Therapeutic areas: OncologyImmunologyEndocrinologyInfectious Diseases
Modalities: Mesenchymal stem cell therapyT-lymphocyte cell therapyTumor-infiltrating lymphocyte (TIL) therapyCAR-NK (Chimeric Antigen Receptor Natural Killer cells)Dendritic cell therapy
Industry: Biotech

Drug pipeline

6 assets

KACM003

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Beijing Biohealthcare Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Biohealthcare Biotechnology Co., Ltd..

Explore the full profile